Gopi ShankerBSc, MSc, PhD
Gopi has spent over seventeen years working in the area of neuroscience drug discovery. He joined the Neuroscience disease area at Novartis in 2013. Prior to joining Novartis, Gopi led several drug discovery programs in the area of neuropsychiatry, neurodegeneration and pain/migraine at Amgen and Regeneron.
At Novartis, Gopi is responsible for setting the strategy and leading the neuropsychiatry unit as well as initiating and establishing drug discovery programs focused on neuropsychiatric and neurodevelopmental disorders leveraging the recent advances in human genetics. Gopi completed his doctoral work in neuroendocrinology at the Indian Institute of Science, Bangalore (India) and his post-doctoral work in sensory neurobiology at the Mt. Sinai School of Medicine, New York.